

OUTLINE OF C-8 BLOOD SAMPLING PROGRAM

AR 226-1567

The sampling program to determine levels of C-8 in employees' blood has several purposes. These are listed below in order of priority. It is felt that an overall communication of intent of program would have a negative impact at this time. Blood sampling as an "overall" program has already been covered in the April 1 communication to employees.

- Pregnant Females - Washington Works

Provide information for physician to use to counsel or reassure about possible pregnancy outcome. Physician's statement and Q&A required (see next page). Prepared by 4/20. Data available for discussing with employees by 4/20.

- Nonpregnant Females - Washington Works

Provide information that the physician can use to advise females on pregnancy planning. Physician's statement, Q&A, and data available 4/20 (see next page).

- Sampling at Germay Park, Circleville, etc.

To confirm previous assessment of exposure for females. Statement and Q&A to be prepared by 4/27. Sampling start _____.

Sampling of Males at Germay Park

To be included to confirm background level.

- Washington Works - Males

Provide information on decay rate of C-8. Sampling in progress.

- Washington Works - Various Groups

Provide data for pregnancy outcome study and confirm background level. Communications to be included in that for epidemiology study if decision is made to proceed.

EID090073

AP002935

WASHINGTON WORKS
OUTLINE OF EMPLOYEE COMMUNICATIONS
BLOOD SAMPLING PROGRAM

In order of priority:

- Inform females removed from Teflon of their blood results - by plant doctor in private.

To do: develop Q&A for doctor to advise:

(A) those with blood levels below
"background" of 0.4 ppm.

(B) those with blood levels above
background.

(C) those in (A) and (B) who are
pregnant.

(D) those in (A) and (B) who de-
sire advice on future preg-
nancies.

(E) effects of blood level on over-
all health of individual.

(F) those who may wish to consult
their physician.

When: Target Date - approved Q&A - 4/20/81

- Inform males of recent blood sampling results.

To do: existing communication procedures are adequate.

When: Ongoing.

EID090074

AP002936

000058

OTHER EMPLOYEE COMMUNICATIONS

- Introduce and encourage support for the "pregnancy outcome" study.

To Do: (a) Communicate study objectives.

(b) Communicate employee participation.

When: Prior to study.

- Update evaluation of blood level results:

To Do: ● Define trends for those still in Teflon Division.

- Define decay rate for those no longer exposed.

- Possible redefinition of "background" levels.

- Update Haskell (and 3M) animal test program.

To do: Define new studies - objectives and timing.

Note: Items 3, 4 and 5 could be combined in one package.

L. F. Percival

4/14/81

EID090075

AJP002937

000059

CC: ERD Division Directors
F. W. Rappaport - N-13519
J. C. Bonnett, M.D.
B. W. Karrh, M.D.

TO: H. G. SMYTH

FROM: BURFORD W. CULPEPPER, M.D. *BWC*

AR226-1568

April 28, 1981

WEEKLY NOTES

C-8 (FC-143)

C-8 (FC-143) blood level testing continues with exposed employees and controls recruited from the Corporate headquarters. 13 controls tested thus far have had non-detectable levels of C-8; i.e., < 0.004 ppm.

Haskell has initiated an animal study this week that may help determine a "no-effect" level in rats. Results will not be available for 60 days.

In the interim, our standard of 0.-0.4 ppm total organic fluorides will continue to be used as a blood level that will not mandate removal of females from the workplace.

BWC:ceb

EID096481

BWK000121

000060